weefselfibrose

weefselfibrose, or tissue fibrosis, is the excessive accumulation of extracellular matrix components, principally collagen, within tissues. This leads to scarring and a progressive loss of normal tissue architecture and function.

It arises after repeated or chronic tissue injury and inflammation. Activated fibroblasts and myofibroblasts synthesize collagen faster than it is degraded, causing remodeling and stiffness. A range of factors can contribute, including infections, autoimmune diseases, toxins, metabolic disorders, radiation, and certain medications.

Common sites include the lungs (pulmonary fibrosis), liver (hepatic fibrosis and cirrhosis), heart, kidneys, and skin. Symptoms vary by organ: shortness of breath and dry cough in lung involvement; fatigue, jaundice or edema in liver disease; chest pain or signs of heart failure with cardiac fibrosis; restricted movement and skin thickening in dermal fibrosis.

Diagnosis relies on medical history, examination, and organ-specific tests. Imaging such as high-resolution CT for lungs or elastography for liver, alongside pulmonary function tests, blood tests, and, in some cases, tissue biopsy, support the diagnosis and staging.

Treatment focuses on slowing progression, treating underlying causes, and managing complications. Anti-fibrotic medications are used for certain fibroses (e.g., pirfenidone and nintedanib for idiopathic pulmonary fibrosis). Other strategies include immunosuppressants when autoimmune disease is involved, lifestyle modifications, and supportive care. In end-stage organ involvement, organ replacement such as liver transplantation may be considered.

Prognosis varies by organ involvement, extent of fibrosis, and response to treatment. Some conditions progress slowly and remain stable for years, while others advance rapidly.

Research continues to uncover mechanisms of fibrosis and to develop targeted therapies that limit scar formation and promote tissue repair.